Skip to main content

Advertisement

SpringerLink
Log in

Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bluming AZ (2022) Safety of systemic hormone replacement therapy in breast cancer survivors. Breast Cancer Res Treat 191:685–686

    Article  CAS  Google Scholar 

  2. Nie W, Ding H, Zou X (2022) Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis.” Breast Cancer Res Treat

  3. Poggio F, Del Mastro L, Bruzzone M et al (2022) Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat 191:269–275

    Article  CAS  Google Scholar 

  4. Marsden J, Whitehead M, A’Hern R et al (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73:292–299

    Article  CAS  Google Scholar 

  5. Kenemans P, Bundred NJ, Foidart J-M et al (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10:135–146

    Article  CAS  Google Scholar 

  6. Borenstein M, Hedges LV, Higgins JPT et al (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1:97–111

    Article  Google Scholar 

  7. Franzoi MA, Agostinetto E, Perachino M, et al (2021) Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol

Download references

Funding

This work received no funding.

Author information

Authors and Affiliations

  1. Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy

    Francesca Poggio

  2. Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

    Marcello Ceppi

  3. Department of Surgical Sciences and Integrated Diagnostic (DISC), School of Medicine, University of Genova, Genova, Italy

    Piero Fregatti

  4. Breast Surgery Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy

    Piero Fregatti

  5. Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy

    Matteo Lambertini & Marco Tagliamento

  6. U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy

    Matteo Lambertini

Authors
  1. Francesca Poggio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcello Ceppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Piero Fregatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matteo Lambertini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco Tagliamento
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matteo Lambertini.

Ethics declarations

Conflict of interest

F.P. declares honoraria and non-financial support from MSD, Eli Lilly, and Novartis outside the submitted work; M.L. declares personal fees from Roche, Novartis, Pfizer, Lilly, Takeda, AstraZeneca, and Sandoz, outside the submitted work; M.T. declares travel, accommodations, and expenses supported by Roche, Bristol-Myers Squibb, AstraZeneca, and Takeda, and activity as a medical writer supported by Novartis and Amgen. All other authors report no disclosures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poggio, F., Ceppi, M., Fregatti, P. et al. Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis”. Breast Cancer Res Treat 194, 709–710 (2022). https://doi.org/10.1007/s10549-022-06590-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-022-06590-8

Search

Navigation